Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow
Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing pre-existing prescriptions tied to the company’s injectable GLP-1. < | Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing pre-existing prescriptions tied to the company’s injectable GLP-1.
TL;DRAI
Novo's Wegovy oral GLP-1 reached 5M patients with $500M Q2 sales and 265K weekly prescriptions since January launch; expanding to UAE, UK, Germany. Supply chain and manufacturing capacity, not product efficacy, are critical to sustaining global momentum and avoiding repeat GLP-1 shortage bottlenecks.
998 words~5 min read
